https://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3PharmaRadar360en2026-09-10T00:00:00.000ZShort-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5PharmaRadar360en2026-09-10T00:00:00.000ZProposals for Individually Safe and Realistic Correction of Antipsychotics in Hospitalized Patients with Schizophrenia: A Prescription Survey at Nagoya University Hospitalhttps://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment of a Rubric for Assessing Essential “Basic Social Skills” Required at the Time of Employment and Its Evaluation in Clinical Traininghttps://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252PharmaRadar360en2026-09-10T00:00:00.000ZClinical Evaluation of Reduced-Dose versus Standard-Dose Remdesivir in Patients with eGFR < 30 mL/min/1.73m<sup>2</sup>: Effectiveness and Safetyhttps://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4PharmaRadar360en2026-09-10T00:00:00.000ZCharacteristics of Medication Errors Prevented by Community Pharmacists During Transition of Carehttps://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49PharmaRadar360en2026-09-10T00:00:00.000ZPharmacist Secondment, Implementation of Ward-based Pharmaceutical Services, and Challenges in Medication Information Sharing during Care Transitionshttps://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026cPharmaRadar360en2026-09-10T00:00:00.000ZContinuous Intervention by an Antimicrobial Stewardship Pharmacist Contributes to Successful Treatment of a Brain Abscess: A Case Reporthttps://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7aPharmaRadar360en2026-09-10T00:00:00.000ZIdentification of Risk Factors for Lithium-Associated Renal Impairment: A Multicenter Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Treatment Continuation and Tolerability Using the Urine Protein-to-Creatinine Ratio (UPC Ratio) as a Criterion for Proteinuria in Patients with Colorectal Cancer Receiving Bevacizumabhttps://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3bPharmaRadar360en2026-09-10T00:00:00.000ZImplementation of the Electronic Tracing Report System and Evaluation of its Usefulnesshttps://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640aPharmaRadar360en2026-09-10T00:00:00.000ZLarval density, development, and distribution of Costelytra giveni in a first-year ryegrass–endophyte grazing trialhttps://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9PharmaRadar360en2026-09-10T00:00:00.000ZIndications of a Dependent Invention for the Use of which a Compulsory License May be Granted in the Pharmaceutical Fieldhttps://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cdPharmaRadar360en2026-09-10T00:00:00.000ZProcedural and Clinical Outcomes of Second-generation Robotic-assisted versus Manual Percutaneous Coronary Intervention: A 1-year Follow-up Studyhttps://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2dPharmaRadar360en2026-09-10T00:00:00.000ZCardiac troponin in pediatric cardiology: toward standardized interpretive frameworks and clinical decision limitshttps://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5PharmaRadar360en2026-09-10T00:00:00.000ZA comparative evaluation of p-tau217 stability in serum and plasma using two validated assayshttps://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713ePharmaRadar360en2026-09-10T00:00:00.000ZDIN SPEC 91532: a process-oriented framework for quality assurance in clinical mass spectrometryhttps://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40PharmaRadar360en2026-09-10T00:00:00.000ZClinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatmenthttps://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358PharmaRadar360en2026-09-10T00:00:00.000ZClinical Impact of Hospital-Associated Disability in Patients With Acute Decompensated Heart Failurehttps://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209acaPharmaRadar360en2026-09-10T00:00:00.000ZHigh-Intensity Statins and the Post-Discharge Clinical Outcomes at 1 Year After Percutaneous Coronary Intervention ― Insights From STOPDAPT-3 ―https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67PharmaRadar360en2026-09-10T00:00:00.000ZEndomyocardial Biopsy and Clinical Outcomes in Acute Myocarditis ― Multicenter Cohort Study ―https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6PharmaRadar360en2026-09-10T00:00:00.000ZDetection of Crystalline Ibuprofen Components in Ibuprofen-Loaded SBA-15 Mesoporous Silica Using Time-Domain NMRhttps://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Water-Related <i>T</i><sub>2</sub> Relaxation Behavior in Hot-Melt Extruded Clotrimazole/PVPVA Solid Dispersions Using Time-Domain NMRhttps://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977ePharmaRadar360en2026-09-10T00:00:00.000ZExploring the Therapeutic Impact of Targeting Brk in Epithelial-Derived Cancer Cellshttps://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235PharmaRadar360en2026-09-10T00:00:00.000ZRealgar Transforming Solution Triggers Ferroptosis-Associated Death in NB4 Leukemia Cells through Disruption of Iron Homeostasis and Suppression of the SLC7A11/GPX4 Axishttps://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7dPharmaRadar360en2026-09-10T00:00:00.000ZCritical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Prioritieshttps://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62PharmaRadar360en2026-09-10T00:00:00.000ZHydrophobic Compounds in the <i>Paeonia suffruticosa</i> Root Cortex Reduce Lipid Accumulation in Adipocytes and the Livers of Obese <i>ob</i>/<i>ob</i> Micehttps://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773bPharmaRadar360en2026-09-10T00:00:00.000Z153ABR: Clinical Procedure Applicationshttps://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dbaPharmaRadar360en2026-09-10T00:00:00.000ZErratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertionshttps://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132PharmaRadar360en2026-09-10T00:00:00.000ZErratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trialshttps://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974PharmaRadar360en2026-09-10T00:00:00.000ZTherapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0PharmaRadar360en2026-09-10T00:00:00.000ZReply to: Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440baPharmaRadar360en2026-09-10T00:00:00.000ZReply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724PharmaRadar360en2026-09-10T00:00:00.000ZIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Studyhttps://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0PharmaRadar360en2026-09-10T00:00:00.000ZHe Was Always Therehttps://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6PharmaRadar360en2026-09-10T00:00:00.000ZOlaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcfPharmaRadar360en2026-09-10T00:00:00.000ZCOMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanomahttps://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60bPharmaRadar360en2026-09-10T00:00:00.000ZRole of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1fPharmaRadar360en2026-09-10T00:00:00.000ZDeveloping a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancerhttps://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faedPharmaRadar360en2026-09-10T00:00:00.000ZShould Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65PharmaRadar360en2026-09-10T00:00:00.000ZSustaining High Reliability Amid Artificial Intelligence Adoption in Oncologyhttps://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6fPharmaRadar360en2026-09-10T00:00:00.000ZOncology Drug Development: Challenges of Increasingly Available Therapieshttps://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbePharmaRadar360en2026-09-10T00:00:00.000ZImpact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Studyhttps://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancerhttps://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaeaPharmaRadar360en2026-09-10T00:00:00.000ZPhase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239PharmaRadar360en2026-09-10T00:00:00.000ZMagrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Studyhttps://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648PharmaRadar360en2026-09-10T00:00:00.000ZThe influence of social media on users’ intention to participate in clinical trials: a cross-country analysis using an adapted technology acceptance modelhttps://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942aPharmaRadar360en2026-09-10T00:00:00.000ZPrice gouging in the B2B pharmaceutical market: a systematic review of unethical pricing, market manipulation, and regulatory challengeshttps://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8ePharmaRadar360en2026-09-10T00:00:00.000ZHypnosis for Postoperative Pain Management Following Colectomies: A Single-Center Randomized Controlled Feasibility Trialhttps://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9PharmaRadar360en2026-09-10T00:00:00.000ZWhen Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surgehttps://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83cPharmaRadar360en2026-09-10T00:00:00.000ZA Virtual Reality Cardiopulmonary Bypass Simulator Versus Conventional Halstedian Observation for Early Perfusion Education: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884PharmaRadar360en2026-09-10T00:00:00.000ZDifferential detection of tau aggregation species using a small molecule probe for cell-based drug screeninghttps://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5PharmaRadar360en2026-09-10T00:00:00.000ZAn explainable AI framework for early mental health screening and clinical decision support using reflective listening and generative AIhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61PharmaRadar360en2026-09-09T23:35:00.000ZHanmi Pharmaceutical Target Price Raised to ₩650,000 as Roche Deal Value Reflectedhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118PharmaRadar360en2026-09-09T23:28:36.000ZUltragenyx Pharmaceutical (RARE) After Aspire Miss And GENGLYCOS Win Has Valuation Back In Focushttps://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662PharmaRadar360en2026-09-09T23:15:22.000ZPortage Biotech (ALP) Financials 2026 - Income Statement and Balance Sheet $ALPhttps://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924PharmaRadar360en2026-09-09T22:42:55.000ZRebuilding Mexico's Pharmaceutical Supply Chainhttps://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868PharmaRadar360en2026-09-09T22:30:47.000ZPharmaceutical company expanding, adding jobs in Hauppaugehttps://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256PharmaRadar360en2026-09-09T21:46:51.000ZLouisiana AG takes FDA and pharmaceutical companies to court over abortion pillshttps://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01PharmaRadar360en2026-09-09T21:34:56.000ZHHS Names Four Senior FDA Officials in Leadership Reorganizationhttps://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183bePharmaRadar360en2026-09-09T21:10:55.000ZGeneration Park is Creating a National Pharmaceutical Hub in Houstonhttps://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcecPharmaRadar360en2026-09-09T20:08:31.000ZMeet Annalina Che, the Scientist Behind Biotech Start-up Darkfin Labshttps://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8PharmaRadar360en2026-09-09T20:05:00.000ZSeismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shockhttps://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ffPharmaRadar360en2026-09-09T19:36:35.000ZTechnology Transfer: Success Drivers and Obstacles Explainedhttps://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70fPharmaRadar360en2026-09-09T18:35:06.000ZKelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase IIIhttps://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7PharmaRadar360en2026-09-09T18:31:44.000ZUS appeals court skeptical of bid to curtail abortion pill accesshttps://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170PharmaRadar360en2026-09-09T18:20:00.000ZNueva convocatoria para realizar prácticas preprofesionaleshttps://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546PharmaRadar360en2026-09-09T18:19:45.000ZU.S. and Tunisian Officials Break Ground on Renovation of Ministry of Health Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591PharmaRadar360en2026-09-09T17:57:47.000ZLeukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideahttps://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5PharmaRadar360en2026-09-09T17:22:54.000ZCUAltos opens registration for the Bachelor's Degree in Pharmaceutical Chemistry and Biologyhttps://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565PharmaRadar360en2026-09-09T16:37:32.000ZNews Today: Satya Niketan collapse a wake-up call to act. But why wait for tragedies? Panellists discuss - India Todayhttps://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dcPharmaRadar360en2026-09-09T16:35:55.000ZPharma’s R&D, commercial approach shifts amid global policy evolutionhttps://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987cPharmaRadar360en2026-09-09T16:32:33.000ZBiotech Fluidics releases upgraded DEGASi inline degasser rangehttps://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818fPharmaRadar360en2026-09-09T16:21:45.000ZBiotech firm uses space to help cells regenerate bodily structureshttps://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6fPharmaRadar360en2026-09-09T16:19:37.000ZAlpha Genesis backs biotech startups with $50M AGI Ventures fundhttps://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1PharmaRadar360en2026-09-09T16:15:33.000ZEU court adviser backs challenge to pharmaceutical wastewater chargeshttps://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114dPharmaRadar360en2026-09-09T16:14:40.000ZKura spins diabetes work into a Lilly-backed biotech startuphttps://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabbPharmaRadar360en2026-09-09T16:07:41.000ZBiotech Stocks To Consider - September 9thhttps://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931PharmaRadar360en2026-09-09T16:06:08.000ZIMA Group to Showcase All-in-One Solutions at CPHI Milanhttps://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0PharmaRadar360en2026-09-09T16:03:22.000ZFAQ: Inside the Latest MFN Deals Signed by Nine Drugmakershttps://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6PharmaRadar360en2026-09-09T15:55:26.000ZFour Biotech Stories Heating Up Right Nowhttps://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966cPharmaRadar360en2026-09-09T15:55:20.000ZFDA fills four senior roles, including top officials for drugs, vaccines and tobaccohttps://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7PharmaRadar360en2026-09-09T15:46:27.000ZHealth Bill: promoting visiting - impact assessmenthttps://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5aPharmaRadar360en2026-09-09T15:46:25.000ZVERAXA Biotech Designates Raju Willener as CFOhttps://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836dPharmaRadar360en2026-09-09T15:46:24.000ZHealth Bill: medical device licensing regime - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-050bf26e4894b2caPharmaRadar360en2026-09-09T15:46:23.000ZHealth Billhttps://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068PharmaRadar360en2026-09-09T15:46:20.000ZHealth Bill: MHRA reforms - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0edPharmaRadar360en2026-09-09T15:46:16.000ZHealth Bill: changes to pharmacy appeals process - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871fPharmaRadar360en2026-09-09T15:46:13.000ZHealth Bill: changes to section 75 of NHS Act 2006 - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996PharmaRadar360en2026-09-09T15:46:09.000ZHealth Bill: patient safety measures - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3PharmaRadar360en2026-09-09T15:46:07.000ZHealth Bill: role and functions of the restructured DHSC - fact sheethttps://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91dPharmaRadar360en2026-09-09T15:46:06.000ZHealth Bill: structural measures to ICBs and foundation trusts - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6ePharmaRadar360en2026-09-09T15:46:04.000ZHealth Bill: providers - fact sheethttps://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1efPharmaRadar360en2026-09-09T15:46:01.000ZHealth Bill: ICBs as strategic commissioners - fact sheethttps://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510PharmaRadar360en2026-09-09T15:45:59.000ZHealth Bill: abolishing NHS England - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9PharmaRadar360en2026-09-09T15:45:54.000ZHealth Bill: ICBs as strategic commissioners - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-impact-assessments-summary-744fa7c4f88e3806PharmaRadar360en2026-09-09T15:45:53.000ZHealth Bill: impact assessments summaryhttps://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-equality-impact-assessment-a15632314deab107PharmaRadar360en2026-09-09T15:45:46.000ZHealth Bill: abolishing NHS England - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-equality-impact-assessments-summary-8eeb40343ce210f9PharmaRadar360en2026-09-09T15:45:40.000ZHealth Bill: equality impact assessments summaryhttps://www.pharmaradar360.com/article/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-th-ab7d5395de69c328PharmaRadar360en2026-09-09T15:41:36.000ZWall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomeshttps://www.pharmaradar360.com/article/health-bill-promoting-visiting-equality-impact-assessment-33c1a8f7b32a87b9PharmaRadar360en2026-09-09T15:40:00.000ZHealth Bill: promoting visiting - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-medicines-and-medical-devices-regulatory-reforms-fact-sheet-7269b5ea8e00e2dfPharmaRadar360en2026-09-09T15:40:00.000ZHealth Bill: medicines and medical devices regulatory reforms - fact sheethttps://www.pharmaradar360.com/article/novartis-s-del-desiran-misses-primary-endpoint-in-phase-3-dm1-trial-99ce4a179960b851PharmaRadar360en2026-09-09T15:31:11.000ZNovartis's Del-Desiran Misses Primary Endpoint in Phase 3 DM1 Trialhttps://www.pharmaradar360.com/article/why-the-biggest-ndc-12-risk-sits-in-the-handoffs-3d5e69a55011a8eaPharmaRadar360en2026-09-09T15:23:19.000ZWhy the Biggest NDC-12 Risk Sits in the Handoffshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-bea04f575ed28a14PharmaRadar360en2026-09-09T15:08:06.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/federal-appeals-court-hears-baseless-challenge-to-the-abortion-pill-mifepristone-940486b7c14cf63fPharmaRadar360en2026-09-09T14:56:47.000ZFederal Appeals Court Hears Baseless Challenge to the Abortion Pill Mifepristone — Againhttps://www.pharmaradar360.com/article/beeline-medicines-19dae1080a3df20cPharmaRadar360en2026-09-09T14:52:27.000ZBeeline Medicineshttps://www.pharmaradar360.com/article/why-account-teams-call-claimguardrx-their-smartest-teammate-24ca28a696436c27PharmaRadar360en2026-09-09T14:24:19.000ZWhy Account Teams Call ClaimGuardRx Their Smartest Teammatehttps://www.pharmaradar360.com/article/the-proprietary-llm-behind-claimguardrx-s-detect-and-respond-engine-756b5ec033050dc5PharmaRadar360en2026-09-09T14:24:19.000ZThe Proprietary LLM Behind ClaimGuardRx's Detect-and-Respond Enginehttps://www.pharmaradar360.com/article/kura-creates-lilly-backed-spinout-armed-with-50m-to-advance-next-gen-diabetes-th-f97b4a180f77d74cPharmaRadar360en2026-09-09T14:20:14.000ZKura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyhttps://www.pharmaradar360.com/article/macrogenics-inexpensive-adc-tce-biotech-with-multiple-catalysts-ahead-nasdaq-mgn-3992c5961012659dPharmaRadar360en2026-09-09T14:15:35.000ZMacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX)https://www.pharmaradar360.com/article/ideaya-biosciences-doses-first-patient-in-phase-3-trial-d00198a17e0c725fPharmaRadar360en2026-09-09T14:10:00.000ZIDEAYA Biosciences Doses First Patient in Phase 3 Trialhttps://www.pharmaradar360.com/article/leerink-partners-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-b4f76e98ec172cbdPharmaRadar360en2026-09-09T14:08:43.000ZLeerink Partners Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/the-transition-to-home-why-confidence-is-critical-to-patient-success-f53fe705f45b7442PharmaRadar360en2026-09-09T13:58:11.000ZThe Transition to Home: Why Confidence is Critical to Patient Successhttps://www.pharmaradar360.com/article/matica-bio-bondwell-partner-on-texas-biotech-d0f4351f2a06e4f3PharmaRadar360en2026-09-09T13:56:05.000ZMatica Bio, Bondwell Partner on Texas Biotechhttps://www.pharmaradar360.com/article/trump-order-directs-federal-push-on-psychedelic-drug-research-and-review-7a02808d8f427079PharmaRadar360en2026-09-09T13:48:15.000ZTrump Order Directs Federal Push on Psychedelic Drug Research and Reviewhttps://www.pharmaradar360.com/article/acrp-launches-2026-27-scholarship-and-grant-application-season-4a9b54371cfd920fPharmaRadar360en2026-09-09T13:45:52.000ZACRP Launches 2026–27 Scholarship and Grant Application Seasonhttps://www.pharmaradar360.com/article/orexin-discoverers-awarded-prestigious-lasker-award-0889c17faef35301PharmaRadar360en2026-09-09T13:43:39.000ZOrexin discoverers awarded prestigious Lasker awardhttps://www.pharmaradar360.com/article/luma-locks-down-15-year-410m-fund-for-life-science-investments-2229e6c1a7656df9PharmaRadar360en2026-09-09T13:43:05.000ZLuma locks down 15-year, $410M fund for life science investmentshttps://www.pharmaradar360.com/article/field-safety-notices-31-august-to-4-september-2026-4fbb5b1daae2c350PharmaRadar360en2026-09-09T13:41:45.000ZField Safety Notices: 31 August to 4 September 2026https://www.pharmaradar360.com/article/nutriband-ceo-gareth-sheridan-to-attend-inaugural-nasdaq-lab-biotech-summit-1307e17da858ae68PharmaRadar360en2026-09-09T13:31:00.000ZNutriband CEO Gareth Sheridan to Attend Inaugural Nasdaq LaB Biotech Summithttps://www.pharmaradar360.com/article/tyra-rolls-toward-pivotal-cancer-study-even-as-stock-deflates-06453e4e0f97fa39PharmaRadar360en2026-09-09T13:30:00.000ZTyra rolls toward pivotal cancer study even as stock deflateshttps://www.pharmaradar360.com/article/five-years-at-bio-mexico-gaining-ground-in-global-biotech-ec0a6f6068da0a75PharmaRadar360en2026-09-09T13:30:00.000ZFive Years at BIO: Mexico Gaining Ground in Global Biotechhttps://www.pharmaradar360.com/article/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-c106ca309e8a6793PharmaRadar360en2026-09-09T13:09:04.000ZGuggenheim Reveals Top Biotech Stock After Positive Clinical Trial Datahttps://www.pharmaradar360.com/article/ocugen-doses-first-patient-in-phase-3-ga-gene-therapy-trial-32970696c462f25bPharmaRadar360en2026-09-09T13:06:06.000ZOcugen doses first patient in phase 3 GA gene therapy trialhttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-734f447a25d821dbPharmaRadar360en2026-09-09T13:03:01.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/viral-haemorrhagic-fever-acdp-algorithm-and-guidance-on-management-of-patients-a442005e4b179dafPharmaRadar360en2026-09-09T13:00:00.000ZViral haemorrhagic fever: ACDP algorithm and guidance on management of patientshttps://www.pharmaradar360.com/article/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-p-39acc0eee159b7fcPharmaRadar360en2026-09-09T13:00:00.000ZImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updateshttps://www.pharmaradar360.com/article/suddenly-this-summer-biotech-breaks-open-with-drug-approvals-ipos-will-it-last-25bef14c1bde5876PharmaRadar360en2026-09-09T12:57:00.000ZSuddenly this summer, biotech breaks open with drug approvals, IPOs. Will it last?https://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-258d162076f199f0PharmaRadar360en2026-09-09T12:42:29.000ZDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientshttps://www.pharmaradar360.com/article/nordic-biotech-ceos-reveal-secret-to-major-funding-and-pharma-deals-a3efea1f52140818PharmaRadar360en2026-09-09T12:37:57.000ZNordic biotech CEOs reveal secret to major funding and pharma dealshttps://www.pharmaradar360.com/article/don-t-ignore-the-insider-selling-in-biomarin-pharmaceutical-c392d2b0a526d595PharmaRadar360en2026-09-09T12:36:40.000ZDon't Ignore The Insider Selling In BioMarin Pharmaceuticalhttps://www.pharmaradar360.com/article/nitrosamines-from-detection-to-understanding-c0e645b8909bb3aaPharmaRadar360en2026-09-09T12:36:38.000ZNitrosamines: from detection to understandinghttps://www.pharmaradar360.com/article/anmat-dispuso-la-baja-de-habilitacion-de-la-firma-rehue-s-a-y-prohibio-sus-produ-95c8696ba780c6c0PharmaRadar360en2026-09-09T12:32:00.000ZANMAT dispuso la baja de habilitación de la firma REHUE S.A. y prohibió sus productos importadoshttps://www.pharmaradar360.com/article/pharmasource-podcast-how-exoz-is-running-a-10-cdmo-rfp-for-cdmo-selection-3a007b19e8cf1ab3PharmaRadar360en2026-09-09T12:31:32.000ZPharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO Selectionhttps://www.pharmaradar360.com/article/a-paid-pilot-will-test-trinity-biotech-cooling-fluids-in-ai-data-centers-7fd633709f73fc8cPharmaRadar360en2026-09-09T12:30:00.000ZA paid pilot will test Trinity Biotech cooling fluids in AI data centershttps://www.pharmaradar360.com/article/over-1-5-billion-to-help-nhs-withstand-year-round-pressure-cbf84c3935b064e9PharmaRadar360en2026-09-09T12:26:00.000ZOver £1.5 billion to help NHS withstand year-round pressurehttps://www.pharmaradar360.com/article/a-narcolepsy-drug-showed-median-reductions-of-up-to-88-8-in-sudden-muscle-loss-a-0ff7d04798652a97PharmaRadar360en2026-09-09T12:24:00.000ZA narcolepsy drug showed median reductions of up to 88.8% in sudden muscle-loss attacks.https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-bfc75e0710215140PharmaRadar360en2026-09-09T12:22:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to July to September 2026https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8PharmaRadar360en2026-09-09T12:13:28.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2025 to August 2026https://www.pharmaradar360.com/article/atmospheric-nox-may-contribute-to-ndsri-formation-study-shows-717a069d3a62c417PharmaRadar360en2026-09-09T12:12:43.000ZAtmospheric NOₓ may contribute to NDSRI formation, study showshttps://www.pharmaradar360.com/article/novartis-back-to-back-phase-3-failures-for-pelacarsen-and-del-desiran-send-share-2bac2be2f578a969PharmaRadar360en2026-09-09T12:10:54.000ZNovartis: Back-to-Back Phase 3 Failures for Pelacarsen and Del-Desiran Send Shares Slidinghttps://www.pharmaradar360.com/article/world-health-expo-to-showcase-trillion-dollar-growth-across-pharma-biotech-longe-6803da287ace71b1PharmaRadar360en2026-09-09T12:07:00.000ZWorld Health Expo to showcase trillion-dollar growth across pharma, biotech, longevity and wellness at 2027 editionhttps://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-may-2e45bd7b86003737PharmaRadar360en2026-09-09T12:06:14.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, May 2026 to May 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-apri-b7f6f80136a72c29PharmaRadar360en2026-09-09T12:06:01.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, April 2026 to April 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-marc-a9688d88c3a30590PharmaRadar360en2026-09-09T12:05:44.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, March 2026 to March 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-febr-df1ca0002f7ddc6bPharmaRadar360en2026-09-09T12:05:28.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, February 2026 to February 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-june-a0324311fd4d4714PharmaRadar360en2026-09-09T12:05:12.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, June 2026 to June 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-july-e4a658a591d9a33ePharmaRadar360en2026-09-09T12:04:56.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, July 2026 to July 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-augu-e29136a0758c031fPharmaRadar360en2026-09-09T12:04:37.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, August 2026 to August 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-dd9b886471b7e27ePharmaRadar360en2026-09-09T12:04:22.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2026 to September 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-63ff575955c0b169PharmaRadar360en2026-09-09T12:04:09.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, October 2026 to October 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-janu-6665f6d4d545e2adPharmaRadar360en2026-09-09T12:03:52.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, January 2026 to January 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-dece-b514e806327cec75PharmaRadar360en2026-09-09T12:03:31.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, December 2025 to December 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-nove-9bc61a228a7791a8PharmaRadar360en2026-09-09T12:03:10.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, November 2025 to November 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-b016e524e13c6091PharmaRadar360en2026-09-09T12:02:44.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, October 2025 to October 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-700ae1d4dc61471fPharmaRadar360en2026-09-09T12:01:51.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2025 to September 2026https://www.pharmaradar360.com/article/a-3-f66515bf33b9f262PharmaRadar360en2026-09-09T12:00:00.000Z血友病A治療薬ヘムライブラを創製した中外製薬の研究者3名が世界的権威のある米国の科学賞「ラスカー賞」を受賞 ～独自の着想で治療体系を変えたバイスペシフィック抗体の発明が評価～https://www.pharmaradar360.com/article/three-chugai-researchers-behind-the-discovery-of-hemlibra-for-hemophilia-a-recei-818232e0bd38792cPharmaRadar360en2026-09-09T12:00:00.000ZThree Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors - Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach –https://www.pharmaradar360.com/article/veradius-unity-and-bv-pulsera-mobile-c-arm-system-9in-and-12in-versions-0cb1d977b3032a6aPharmaRadar360en2026-09-09T12:00:00.000ZVeradius Unity and BV Pulsera Mobile C-Arm System-9in. and 12in. Versionshttps://www.pharmaradar360.com/article/philips-ingenia-achieva-and-intera-mr-systems-b7e6009e9e3fb961PharmaRadar360en2026-09-09T12:00:00.000ZPhilips Ingenia, Achieva and Intera MR Systemshttps://www.pharmaradar360.com/article/court-of-appeals-hears-oral-arguments-in-louisiana-abortion-pill-lawsuit-50fa9321f5302288PharmaRadar360en2026-09-09T11:50:02.000ZCourt of Appeals hears oral arguments in Louisiana abortion pill lawsuithttps://www.pharmaradar360.com/article/ganesh-chaturthi-2026-mumbai-s-12-000-ganesh-mandals-under-fda-scanner-over-pras-be7950d397f186f7PharmaRadar360en2026-09-09T11:27:31.000ZGanesh Chaturthi 2026: Mumbai’s 12,000 Ganesh mandals under FDA scanner over prasad, bhandara food...https://www.pharmaradar360.com/article/mirum-pharmaceuticals-hires-lmh-strategic-solutions-284e103ab1270aa8PharmaRadar360en2026-09-09T11:24:08.000ZMirum Pharmaceuticals Hires LMH Strategic Solutionshttps://www.pharmaradar360.com/article/decision-advertising-investigations-august-2026-0b95edb50287d7e6PharmaRadar360en2026-09-09T11:23:46.000ZDecision: Advertising investigations: August 2026https://www.pharmaradar360.com/article/article-141-1-procedure-quarter-based-selective-dry-cow-therapy-dc21887708f5021bPharmaRadar360en2026-09-09T11:22:42.000ZArticle 141(1) procedure: Quarter-based selective dry cow therapyhttps://www.pharmaradar360.com/article/141-1-7a946e163c61ea87PharmaRadar360en2026-09-09T11:20:59.000ZΔιαδικασία βάσει του άρθρου 141(1): Επιλεκτική θεραπεία κατά την ξηρά περίοδο ανά τεταρτημόριο μαστικού αδέναhttps://www.pharmaradar360.com/article/meningococcal-disease-guidance-data-and-analysis-cf4d903cf180377aPharmaRadar360en2026-09-09T11:16:48.000ZMeningococcal disease: guidance, data and analysishttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-june-2027-bab1705385315cdaPharmaRadar360en2026-09-09T11:15:47.000ZAdult social care client level data, England: quarterly update to June 2027https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2026-404dfd4156db3fd3PharmaRadar360en2026-09-09T11:15:13.000ZAdult social care client level data, England: quarterly update to September 2026https://www.pharmaradar360.com/article/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-9da1ba6971e41fb4PharmaRadar360en2026-09-09T11:06:58.000ZOpus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027https://www.pharmaradar360.com/article/kane-biotech-to-host-commercial-update-webcast-on-september-16-9a8886880a182539PharmaRadar360en2026-09-09T11:05:00.000ZKane Biotech to Host Commercial Update Webcast on September 16https://www.pharmaradar360.com/article/algorithmic-tool-may-improve-screening-of-patients-for-an-alzheimer-s-clinical-t-562efba4ceb9605dPharmaRadar360en2026-09-09T11:00:07.000ZAlgorithmic tool may improve screening of patients for an Alzheimer's clinical trialhttps://www.pharmaradar360.com/article/fda-is-still-reviewing-rezolute-s-experimental-drug-no-timeline-is-set-cf406d8464aac8e4PharmaRadar360en2026-09-09T11:00:00.000ZFDA is still reviewing Rezolute’s experimental drug. No timeline is set.https://www.pharmaradar360.com/article/beeline-flies-into-ph-3-as-oral-lupus-drug-soars-past-placebo-303874c2252c60b3PharmaRadar360en2026-09-09T11:00:00.000ZBeeline flies into ph. 3 as oral lupus drug soars past placebohttps://www.pharmaradar360.com/article/exclusive-cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic-817e254766ff52c2PharmaRadar360en2026-09-09T11:00:00.000ZExclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinichttps://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-0849105330920f96PharmaRadar360en2026-09-09T11:00:00.000ZMatica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovationhttps://www.pharmaradar360.com/article/schrodinger-births-new-immunology-and-inflammation-biotech-tectora-therapeutics-3c2ecfcd5bb63fb8PharmaRadar360en2026-09-09T10:58:37.000ZSchrödinger births new immunology and inflammation biotech, Tectora Therapeuticshttps://www.pharmaradar360.com/article/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-398cbf270d73588bPharmaRadar360en2026-09-09T10:58:37.000ZSolstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2https://www.pharmaradar360.com/article/the-manufacturing-questions-facing-chinese-biotech-cf50d2874a8599bePharmaRadar360en2026-09-09T10:56:57.000ZThe Manufacturing Questions Facing Chinese Biotechhttps://www.pharmaradar360.com/article/moonwalk-banks-70m-to-progress-sirna-therapy-for-obesity-de269d2e1175ff14PharmaRadar360en2026-09-09T10:50:27.000ZMoonwalk banks $70m to progress siRNA therapy for obesityhttps://www.pharmaradar360.com/article/unparalleled-opportunity-sandoz-embarks-on-ambitious-biosimilar-growth-strategy-676c4323204a4fcfPharmaRadar360en2026-09-09T10:49:50.000Z“Unparalleled opportunity”: Sandoz embarks on ambitious biosimilar growth strategyhttps://www.pharmaradar360.com/article/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-deve-9e7da1cb20ba16a8PharmaRadar360en2026-09-09T10:46:40.000ZMannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Managementhttps://www.pharmaradar360.com/article/a-rapid-acting-short-duration-inhaled-treatment-is-being-developed-for-weight-ma-e383768e6e897a31PharmaRadar360en2026-09-09T10:30:00.000ZA rapid-acting, short-duration inhaled treatment is being developed for weight managementhttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-6902f574353aeb80PharmaRadar360en2026-09-09T10:28:01.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/what-makes-pharmaceutical-speaker-programs-illegal-f87d152b9ae8d979PharmaRadar360en2026-09-09T10:10:00.000ZWhat Makes Pharmaceutical Speaker Programs Illegal?https://www.pharmaradar360.com/article/a-global-eye-cancer-trial-has-dosed-its-first-patient-529d4d314833481cPharmaRadar360en2026-09-09T10:00:00.000ZA global eye cancer trial has dosed its first patienthttps://www.pharmaradar360.com/article/biden-era-abortion-by-mail-rules-face-key-test-at-appeals-court-hearing-0cd9e746f1b92012PharmaRadar360en2026-09-09T10:00:00.000ZBiden-era abortion by mail rules face key test at appeals court hearinghttps://www.pharmaradar360.com/article/nafdac-and-nhrec-announce-new-dates-for-mandatory-stakeholders-training-on-clini-c75adb4ff13bd3afPharmaRadar360en2026-09-09T09:53:32.000ZNAFDAC and NHREC Announce New Dates for Mandatory Stakeholders Training on Clinical Trial Regulations in Nigeriahttps://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-among-independent-f32c88a42723b612PharmaRadar360en2026-09-09T09:50:37.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections among independent sector providers: experimental statistics, April 2025 to March 2026https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-4-returnees-from-an-ebola-affected-3451106449dc4cbdPharmaRadar360en2026-09-09T08:30:05.000ZEbola disease: information sheet for category 4 returnees from an Ebola-affected areahttps://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-3-returnees-from-an-ebola-affected-66d6f6455dcf6d66PharmaRadar360en2026-09-09T08:30:05.000ZEbola disease: information sheet for category 3 returnees from an Ebola-affected areahttps://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-2-returnees-from-an-ebola-affected-0ad9eb86ec575c6fPharmaRadar360en2026-09-09T08:30:05.000ZEbola disease: information sheet for category 2 returnees from an Ebola-affected areahttps://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-1-returnees-from-an-ebola-affected-24c7b8b02c106176PharmaRadar360en2026-09-09T08:30:05.000ZEbola disease: information sheet for category 1 returnees from an Ebola-affected areahttps://www.pharmaradar360.com/article/ebola-and-marburg-contact-matrix-for-returning-workers-scheme-and-non-uk-exposur-dedb115fc574e9fePharmaRadar360en2026-09-09T08:30:05.000ZEbola and Marburg: contact matrix for Returning Workers Scheme and non-UK exposureshttps://www.pharmaradar360.com/article/ebola-virus-disease-clinical-management-and-guidance-74343e283fe62dbcPharmaRadar360en2026-09-09T08:30:05.000ZEbola virus disease: clinical management and guidancehttps://www.pharmaradar360.com/article/ebola-returning-workers-scheme-public-health-advice-3f98a3a732b6c31cPharmaRadar360en2026-09-09T08:30:05.000ZEbola returning workers scheme: public health advicehttps://www.pharmaradar360.com/article/barclays-upgrades-sagimet-stock-rating-on-acne-drug-potential-ae3e9d55d7da7baaPharmaRadar360en2026-09-09T08:08:00.000ZBarclays upgrades Sagimet stock rating on acne drug potentialhttps://www.pharmaradar360.com/article/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-chi-0c539f69c1cd457cPharmaRadar360en2026-09-09T08:04:29.000ZOral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trialhttps://www.pharmaradar360.com/article/a-sleep-apnea-measure-rose-10-4-with-an-experimental-drug-versus-49-2-with-place-90e8edbb76843343PharmaRadar360en2026-09-09T08:00:00.000ZA sleep-apnea measure rose 10.4% with an experimental drug, versus 49.2% with placebohttps://www.pharmaradar360.com/article/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-7689bcdaf1ae338aPharmaRadar360en2026-09-09T07:34:54.000ZMosliciguat Advances to Phase 3 PHrontier Trial After PHocus Study Shows 20% PVR Reductionhttps://www.pharmaradar360.com/article/medicine-shortages-grow-in-iran-as-us-tightens-sanctions-blockade-ecd987fe722f5a4ePharmaRadar360en2026-09-09T07:20:42.000ZMedicine shortages grow in Iran as US tightens sanctions, blockadehttps://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-food-safety-violators-5fff85b007469683PharmaRadar360en2026-09-09T06:07:05.000ZMaharashtra FDA Cracks Down on Food Safety Violatorshttps://www.pharmaradar360.com/article/maharashtra-fda-suspends-food-licenses-of-railway-catering-supplier-20-eateries-c5fd85665f97fc76PharmaRadar360en2026-09-09T06:02:00.000ZMaharashtra FDA suspends food licenses of railway catering supplier, 20 eateries over alleged violations of safety normshttps://www.pharmaradar360.com/article/steady-stream-of-crossover-rounds-stock-biotech-s-ipo-pipeline-dbbe4746af7c54edPharmaRadar360en2026-09-09T04:17:42.000ZSteady stream of crossover rounds stock biotech’s IPO pipelinehttps://www.pharmaradar360.com/article/ibento-ibento-report-on-the-pmda-hokuriku-branch-10th-anniversary-symposium-c1a0e57e7ec099d8PharmaRadar360en2026-09-09T03:00:00.000Z[IBENTO][IBENTO]Report on the PMDA Hokuriku Branch 10th Anniversary Symposiumhttps://www.pharmaradar360.com/article/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-af705b30fbefc4ccPharmaRadar360en2026-09-09T02:26:00.000ZTaiwan's Obigen Pharma to Unblind Phase 3 Botox Trial Early in November; Year-End Cash Raise to Top NT$400 Millionhttps://www.pharmaradar360.com/article/wegovy-and-mounjaro-for-weight-loss-not-funded-a2a3ffb1738d2e00PharmaRadar360en2026-09-09T02:00:00.000ZWegovy and Mounjaro for weight loss not fundedhttps://www.pharmaradar360.com/article/many-different-paths-may-lead-to-a-role-in-clinical-project-management-96598feaeb50c516PharmaRadar360en2026-09-09T00:39:13.000ZMany Different Paths May Lead to a Role in Clinical Project Managementhttps://www.pharmaradar360.com/article/click-e-stock-one-novartis-new-drug-fails-phase-3-target-price-for-alteogen-lowe-7cafc5a1c226a35dPharmaRadar360en2026-09-09T00:23:54.000Z[Click e-Stock] "One Novartis New Drug Fails Phase 3" Target Price for Alteogen Loweredhttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-9e8f3bd2a58b229cPharmaRadar360en2026-09-09T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-0a518003195b02c6PharmaRadar360en2026-09-09T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-e335cd1b22d70e1fPharmaRadar360en2026-09-09T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-9aa625139ac75227PharmaRadar360en2026-09-09T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-1e47573291afd54fPharmaRadar360en2026-09-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-8eb3d6242be7cf81PharmaRadar360en2026-09-09T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-930c63ad0185a524PharmaRadar360en2026-09-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e89a231cfd924a47PharmaRadar360en2026-09-09T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a78f64ffb4d5c5bcPharmaRadar360en2026-09-09T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f72c07194289862ePharmaRadar360en2026-09-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-4c8b30d98486094cPharmaRadar360en2026-09-09T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-326f5ae30be376d1PharmaRadar360en2026-09-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a5ee3eb788954281PharmaRadar360en2026-09-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-24899144f167d31ePharmaRadar360en2026-09-09T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-20eab0fecbf9a929PharmaRadar360en2026-09-09T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-385c389d5cd84eeePharmaRadar360en2026-09-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-pro-bff9d18f307f05a1PharmaRadar360en2026-09-09T00:00:00.000ZTemporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-es-b6fb3f98dd33049bPharmaRadar360en2026-09-09T00:00:00.000ZVaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-2027 Southern Hemisphere Influenza Virus Vaccineshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-hum-9e81e95c6000ebb0PharmaRadar360en2026-09-09T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Productshttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-99f349f787d2f97ePharmaRadar360en2026-09-09T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andem-d38ea0d42ee8ba36PharmaRadar360en2026-09-09T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRYhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pre-8f9c9e790ba2b6a8PharmaRadar360en2026-09-09T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communicationshttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzup-eeb61cd6a595bf0bPharmaRadar360en2026-09-09T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; ANZUPGOhttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ankti-9840243fd9e98d18PharmaRadar360en2026-09-09T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVAhttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-bee1e53401727a8fPharmaRadar360en2026-09-09T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/reorganization-of-the-national-center-for-immunization-and-respiratory-diseases-588d95ecfd03eea8PharmaRadar360en2026-09-09T00:00:00.000ZReorganization of the National Center for Immunization and Respiratory Diseaseshttps://www.pharmaradar360.com/article/tips-for-dealing-with-empty-nest-syndrome-64aa3c260d31a871PharmaRadar360en2026-09-09T00:00:00.000ZTips for Dealing With Empty Nest Syndromehttps://www.pharmaradar360.com/article/cleveland-clinic-partners-with-luminai-to-transform-health-system-operations-8b1951904a6aedefPharmaRadar360en2026-09-09T00:00:00.000ZCleveland Clinic Partners with Luminai to Transform Health System Operationshttps://www.pharmaradar360.com/article/beyond-70-000-reassessing-the-global-fontan-population-through-citation-chain-an-b1ba1fb432aad77cPharmaRadar360en2026-09-09T00:00:00.000ZBeyond 70,000: Reassessing the Global Fontan Population Through Citation-Chain Analysis and Tiered Epidemiologic Estimationhttps://www.pharmaradar360.com/article/neo-adjuvant-approvals-for-solid-tumors-by-the-us-food-and-drug-administration-2-756ed3abf614efc6PharmaRadar360en2026-09-09T00:00:00.000Z(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.https://www.pharmaradar360.com/article/a-phase-3-trial-of-vosoritide-in-children-with-hypochondroplasia-6de4f09ea4b05915PharmaRadar360en2026-09-09T00:00:00.000ZA Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.https://www.pharmaradar360.com/article/association-of-i-helicobacter-pylori-i-infection-with-insulin-resistance-tumor-n-316790c378779761PharmaRadar360en2026-09-09T00:00:00.000ZAssociation of <i>Helicobacter pylori</i> infection with insulin resistance, tumor necrosis factor-alpha, and dyslipidemia in obese children with metabolic syndromehttps://www.pharmaradar360.com/article/phenomenology-in-pediatric-nursing-lessons-from-studies-of-mothers-caring-for-ch-4f3fffea388d6bfePharmaRadar360en2026-09-09T00:00:00.000ZPhenomenology in pediatric nursing: Lessons from studies of mothers caring for children with chronic illnesseshttps://www.pharmaradar360.com/article/utilizing-a-smartphone-application-for-perinatal-depression-screening-and-care-l-d1657f9c0ce56b10PharmaRadar360en2026-09-09T00:00:00.000ZUtilizing a Smartphone Application for Perinatal Depression Screening and Care Linkageshttps://www.pharmaradar360.com/article/network-biology-to-artificial-intelligence-building-the-next-generation-of-predi-7049814c4b1b0ea9PharmaRadar360en2026-09-09T00:00:00.000ZNetwork biology to artificial intelligence: building the next generation of predictive drug discoveryhttps://www.pharmaradar360.com/article/interactions-of-nanoparticles-with-structures-of-the-respiratory-system-nanopart-6e7d20d5c4593f8dPharmaRadar360en2026-09-09T00:00:00.000ZInteractions of Nanoparticles with Structures of the Respiratory System, Nanoparticle Endocytosis by Cells and Cell Responseshttps://www.pharmaradar360.com/article/inhaled-nanoliposomes-for-treating-lung-disease-including-a-case-study-of-amikac-5c581901e1fef964PharmaRadar360en2026-09-09T00:00:00.000ZInhaled Nanoliposomes for Treating Lung Disease Including a Case Study of Amikacin Liposome Inhalation Suspension (ALIS)https://www.pharmaradar360.com/article/drug-delivering-particles-aim-to-breach-the-blood-brain-barrier-6b0773077796d0f1PharmaRadar360en2026-09-09T00:00:00.000ZDrug-delivering particles aim to breach the blood–brain barrierhttps://www.pharmaradar360.com/article/mechanical-basis-of-cortical-cataract-214599f9167e95cePharmaRadar360en2026-09-09T00:00:00.000ZMechanical basis of cortical cataracthttps://www.pharmaradar360.com/article/nct07811128-leveraging-digital-health-solutions-to-collect-patient-reported-outc-de9c163ffaa5b58ePharmaRadar360en2026-09-09T00:00:00.000ZNCT07811128: Leveraging Digital Health Solutions to Collect Patient-Reported Outcomes in Rectal Cancerhttps://www.pharmaradar360.com/article/nct07810855-using-bedside-ultrasound-to-understand-fluid-management-in-patients-f01e5454fd815262PharmaRadar360en2026-09-09T00:00:00.000ZNCT07810855: Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Diseasehttps://www.pharmaradar360.com/article/nct07810231-prospective-longitudinal-cohort-study-of-implant-age-pocket-plane-in-f1335f5a7fd090e7PharmaRadar360en2026-09-09T00:00:00.000ZNCT07810231: Prospective Longitudinal Cohort Study of Implant Age, Pocket Plane, Incision, Surface Texture, and Volume as Predictors of Clinically Significant Capsular Contracturehttps://www.pharmaradar360.com/article/nct07809542-brain-network-characteristics-of-pain-patients-based-on-magnetoencep-f1102e08355c2f4aPharmaRadar360en2026-09-09T00:00:00.000ZNCT07809542: Brain Network Characteristics of Pain Patients Based on Magnetoencephalographyhttps://www.pharmaradar360.com/article/nct07809438-a-comparative-performance-study-between-high-and-standard-resolution-a7b9283bcd325474PharmaRadar360en2026-09-09T00:00:00.000ZNCT07809438: A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07809399-volumetric-hrct-in-stable-copd-patients-905336f1346cda49PharmaRadar360en2026-09-09T00:00:00.000ZNCT07809399: Volumetric HRCT in Stable COPD Patients.https://www.pharmaradar360.com/article/nct07809087-feasibility-study-of-an-interactive-wall-based-intervention-program-68f2eb96ca9dbf6ePharmaRadar360en2026-09-09T00:00:00.000ZNCT07809087: Feasibility Study of an Interactive Wall-Based Intervention Program for Nursing Home Residents and Patients in Long-Term Care Facilities: Mur'Aventurehttps://www.pharmaradar360.com/article/nct07809074-mindfulness-and-self-compassion-intervention-for-ostomy-patients-due-928772f3ba63ee88PharmaRadar360en2026-09-09T00:00:00.000ZNCT07809074: Mindfulness and Self-Compassion Intervention for Ostomy Patients Due to Colorectal Cancer on Loneliness (MSC-OP)https://www.pharmaradar360.com/article/nct07808645-wearable-sleep-eeg-and-auditory-stimulation-in-healthy-adults-a3f895f1435a9f4ePharmaRadar360en2026-09-09T00:00:00.000ZNCT07808645: Wearable Sleep EEG and Auditory Stimulation in Healthy Adultshttps://www.pharmaradar360.com/article/nct07803471-yiqi-fumai-lyophilized-injection-for-chronic-heart-failure-caused-by-a2f07156d8dd8c5fPharmaRadar360en2026-09-09T00:00:00.000ZNCT07803471: Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Diseasehttps://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464PharmaRadar360en2026-09-09T00:00:00.000ZNCT07796373: Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitorhttps://www.pharmaradar360.com/article/nct07770919-continuous-theta-burst-stimulation-for-generalized-anxiety-disorder-a11ec2e143861103PharmaRadar360en2026-09-09T00:00:00.000ZNCT07770919: Continuous Theta Burst Stimulation for Generalized Anxiety Disorderhttps://www.pharmaradar360.com/article/nct07755748-glaucoma-screening-to-enhance-at-risk-californians-health-survey-res-613aad5046be38a3PharmaRadar360en2026-09-09T00:00:00.000ZNCT07755748: Glaucoma Screening to Enhance At-Risk Californians' Health - Survey Response Incentiveshttps://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00PharmaRadar360en2026-09-09T00:00:00.000ZNCT07686380: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapyhttps://www.pharmaradar360.com/article/nct07668518-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-53495f0e626ad570PharmaRadar360en2026-09-09T00:00:00.000ZNCT07668518: A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPDhttps://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62cPharmaRadar360en2026-09-09T00:00:00.000ZNCT07667400: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancerhttps://www.pharmaradar360.com/article/nct07645443-feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-i-e6b3a6106587bc2aPharmaRadar360en2026-09-09T00:00:00.000ZNCT07645443: FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosishttps://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762PharmaRadar360en2026-09-09T00:00:00.000ZNCT07524530: Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancershttps://www.pharmaradar360.com/article/nct07509034-autologous-b7-h3-chimeric-antigen-receptor-t-cells-in-previously-tre-2b314a9db8642130PharmaRadar360en2026-09-09T00:00:00.000ZNCT07509034: Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Diseasehttps://www.pharmaradar360.com/article/nct07447557-study-of-intrathecal-elp-02-for-charcot-marie-tooth-disease-type-4j-9df85b59b7760510PharmaRadar360en2026-09-09T00:00:00.000ZNCT07447557: Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)https://www.pharmaradar360.com/article/nct07436728-a-study-of-tak-505-in-adults-with-solid-tumors-0ceaf12c08fe7644PharmaRadar360en2026-09-09T00:00:00.000ZNCT07436728: A Study of TAK-505 in Adults With Solid Tumorshttps://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2aPharmaRadar360en2026-09-09T00:00:00.000ZNCT07262983: Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitishttps://www.pharmaradar360.com/article/nct07241377-a-study-in-healthy-adults-to-compare-the-bioavailability-of-epa-dha-04a145623e5fd712PharmaRadar360en2026-09-09T00:00:00.000ZNCT07241377: A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebohttps://www.pharmaradar360.com/article/nct07234942-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-934403a64baf19fbPharmaRadar360en2026-09-09T00:00:00.000ZNCT07234942: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)https://www.pharmaradar360.com/article/nct07224763-study-to-evaluate-the-safety-and-efficacy-of-the-ggta1-ko-thymokidne-e7469684f1a340a9PharmaRadar360en2026-09-09T00:00:00.000ZNCT07224763: Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDhttps://www.pharmaradar360.com/article/nct07210398-mindfulness-based-cognitive-therapy-for-the-chronic-pain-early-cogni-a5c8ad0779df2ad7PharmaRadar360en2026-09-09T00:00:00.000ZNCT07210398: Mindfulness-based Cognitive Therapy for the Chronic Pain-early Cognitive Decline Co-morbidity Among Older Black Individuals in the Community; The Feeling of Being Open Pilothttps://www.pharmaradar360.com/article/nct07205107-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combinat-c2ef75272e264556PharmaRadar360en2026-09-09T00:00:00.000ZNCT07205107: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgarishttps://www.pharmaradar360.com/article/nct07166094-study-to-assess-the-efficacy-and-safety-of-rina-s-compared-to-treatm-654bf6bd00153589PharmaRadar360en2026-09-09T00:00:00.000ZNCT07166094: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancerhttps://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72PharmaRadar360en2026-09-09T00:00:00.000ZNCT07137442: Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniqueshttps://www.pharmaradar360.com/article/nct06851806-study-of-palivizumab-in-children-with-high-risk-of-severe-respirator-030ea64e3955972aPharmaRadar360en2026-09-09T00:00:00.000ZNCT06851806: Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Diseasehttps://www.pharmaradar360.com/article/nct06825702-safety-tolerability-and-efficacy-of-intravitreal-kio-104-in-patients-8d4299ce7f4765dcPharmaRadar360en2026-09-09T00:00:00.000ZNCT06825702: Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edemahttps://www.pharmaradar360.com/article/nct06782308-tinnitus-patient-preferences-survey-717b4fa3f14c3c2bPharmaRadar360en2026-09-09T00:00:00.000ZNCT06782308: Tinnitus Patient Preferences Surveyhttps://www.pharmaradar360.com/article/nct06578520-effect-of-the-use-of-dapagliflozin-in-patients-with-refractory-heart-ed2d60e95fd26467PharmaRadar360en2026-09-09T00:00:00.000ZNCT06578520: Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failurehttps://www.pharmaradar360.com/article/nct06548412-ctx-009-with-gemcitabine-cisplatin-and-durvalumab-as-first-line-ther-2b2fdba90bbebbbaPharmaRadar360en2026-09-09T00:00:00.000ZNCT06548412: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancershttps://www.pharmaradar360.com/article/nct06470048-a-clinical-study-to-evaluate-ianalumab-in-participants-with-diffuse-81b10aa4165bd17cPharmaRadar360en2026-09-09T00:00:00.000ZNCT06470048: A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosishttps://www.pharmaradar360.com/article/nct06410248-triapine-in-combination-with-temozolomide-for-the-treatment-of-patie-0cf1d97b4e719323PharmaRadar360en2026-09-09T00:00:00.000ZNCT06410248: Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct06323161-a-research-study-to-see-how-much-cagrisema-lowers-blood-sugar-and-bo-7b5290a15f28fde0PharmaRadar360en2026-09-09T00:00:00.000ZNCT06323161: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metforminhttps://www.pharmaradar360.com/article/nct06260228-home-based-self-management-and-cognitive-training-changes-lives-hobs-ff1e48edbb3a2369PharmaRadar360en2026-09-09T00:00:00.000ZNCT06260228: HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)https://www.pharmaradar360.com/article/nct06235801-a-phase-i-ii-study-of-gilteritinib-and-momelotinib-for-patients-with-1fe17411a66cc840PharmaRadar360en2026-09-09T00:00:00.000ZNCT06235801: A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemiahttps://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563PharmaRadar360en2026-09-09T00:00:00.000ZNCT06052631: Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Genehttps://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459PharmaRadar360en2026-09-09T00:00:00.000ZNCT05713799: Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesityhttps://www.pharmaradar360.com/article/nct05706558-retrospective-review-of-esophageal-cancer-at-mskcc-cafd4ee1a7b70879PharmaRadar360en2026-09-09T00:00:00.000ZNCT05706558: Retrospective Review of Esophageal Cancer at MSKCChttps://www.pharmaradar360.com/article/nct05570253-a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-bre-7c04db2a9102a2cePharmaRadar360en2026-09-09T00:00:00.000ZNCT05570253: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancerhttps://www.pharmaradar360.com/article/nct05232071-placebo-controlled-proof-of-concept-study-to-evaluate-the-safety-and-9fcfbde442103736PharmaRadar360en2026-09-09T00:00:00.000ZNCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitushttps://www.pharmaradar360.com/article/nct05037461-precision-radiotherapy-using-mr-linac-for-pancreatic-neuroendocrine-fcedc2d84f591031PharmaRadar360en2026-09-09T00:00:00.000ZNCT05037461: Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patientshttps://www.pharmaradar360.com/article/nct04847648-air-polishing-in-the-treatment-of-peri-implantitis-7fadfb7a67b10d53PharmaRadar360en2026-09-09T00:00:00.000ZNCT04847648: Air-polishing in the Treatment of Peri-implantitishttps://www.pharmaradar360.com/article/nct04542824-trial-of-the-safety-and-efficacy-of-epcoritamab-in-japanese-subjects-8f8b2e5edddf7421PharmaRadar360en2026-09-09T00:00:00.000ZNCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)https://www.pharmaradar360.com/article/nct04124497-a-trial-for-relapsed-and-relapsed-refractory-multiple-myeloma-patien-96886e54e668bcc6PharmaRadar360en2026-09-09T00:00:00.000ZNCT04124497: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patientshttps://www.pharmaradar360.com/article/nct03625037-first-in-human-fih-trial-in-patients-with-relapsed-progressive-or-re-7c8817969428243dPharmaRadar360en2026-09-09T00:00:00.000ZNCT03625037: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphomahttps://www.pharmaradar360.com/article/nct03549754-icareme-global-registry-multinational-real-world-evidence-in-cardior-ca8b38986b5aecf0PharmaRadar360en2026-09-09T00:00:00.000ZNCT03549754: iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseaseshttps://www.pharmaradar360.com/article/nct03307109-quality-of-life-in-patients-having-a-prosthetic-joint-infection-2572312124caf8f4PharmaRadar360en2026-09-09T00:00:00.000ZNCT03307109: Quality of Life in Patients Having a Prosthetic Joint Infectionhttps://www.pharmaradar360.com/article/nct02890329-ipilimumab-and-decitabine-in-treating-patients-with-relapsed-or-refr-cc9d070597ff8255PharmaRadar360en2026-09-09T00:00:00.000ZNCT02890329: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia